DAFNA Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

DAFNA Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.9M	Buy	48,469 +25,292	+109%	+$5.91M	2.47%	12
2026 Q1	$5.3M	Sell	23,177 -5,000	-18%	-$1.12M	1.21%	24
2025 Q4	$6.01M	Sell	28,177 -5,000	-15%	-$1.03M	1.4%	15
2025 Q3	$6.6M	Sell	33,177 -39,500	-54%	-$7.37M	1.63%	15
2025 Q2	$12.5M	Sell	72,677 -7,721	-10%	-$1.26M	3.46%	10
2025 Q1	$12.5M	Sell	80,398 -22,957	-22%	-$3.28M	3.55%	10
2024 Q4	$14.2M	Buy	103,355 +13,783	+15%	+$1.81M	3.62%	7
2024 Q3	$13.4M	Buy	89,572 +8,600	+11%	+$1.16M	3.16%	9
2024 Q2	$11M	Sell	80,972 -11,500	-12%	-$1.56M	2.64%	11
2024 Q1	$14M	Sell	92,472 -31,000	-25%	-$4.42M	3.18%	10
2023 Q4	$15.6M	Sell	123,472 -12,740	-9%	-$1.27M	3.73%	6
2023 Q3	$12.8M	Buy	136,212 +1,000	+0.7%	+$93.6K	3.97%	6
2023 Q2	$12.1M	Hold	135,212	–	–	3.3%	7
2023 Q1	$14.5M	Buy	135,212 +5,000	+4%	+$572K	4.35%	4
2022 Q4	$15.9M	Sell	130,212 -5,500	-4%	-$639K	4.48%	3
2022 Q3	$14M	Sell	135,712 -3,500	-3%	-$332K	3.77%	5
2022 Q2	$12.9M	Buy	139,212 +108,600	+355%	+$10.2M	3.53%	8
2022 Q1	$3.59M	Buy	30,612 +19,612	+178%	+$2.27M	0.94%	30
2021 Q4	$1.48M	Buy	+11,000	New	+$1.64M	0.37%	54
2021 Q3	–	Sell	-7,137	Closed	-$939K	–	83
2021 Q2	$939K	Sell	7,137 -16,100	-69%	-$2.15M	0.2%	73
2021 Q1	$3M	Hold	23,237	–	–	0.71%	35
2020 Q4	$3.88M	Sell	23,237 -6,000	-21%	-$992K	1.15%	23
2020 Q3	$4.51M	Buy	29,237 +15,000	+105%	+$2.16M	1.47%	18
2020 Q2	$2.11M	Sell	14,237 -19,500	-58%	-$2.68M	0.61%	39
2020 Q1	$3.8M	Buy	33,737 +5,637	+20%	+$732K	1.59%	20
2019 Q4	$3.91M	Sell	28,100 -32,380	-54%	-$3.6M	1.34%	20
2019 Q3	$5.83M	Buy	60,480 +1,100	+2%	+$123K	2.19%	10
2019 Q2	$6.84M	Buy	59,380 +15,000	+34%	+$1.79M	2.57%	6
2019 Q1	$5.22M	Sell	44,380 -32,862	-43%	-$2.88M	2.25%	12
2018 Q4	$4.84M	Hold	77,242	–	–	2.41%	11
2018 Q3	$5.47M	Buy	77,242 +3,497	+5%	+$241K	2.25%	11
2018 Q2	$4.91M	Sell	73,745 -5,500	-7%	-$362K	2.3%	12
2018 Q1	$5.18M	Sell	79,245 -45,394	-36%	-$2.55M	2.52%	10
2017 Q4	$4.99M	Buy	124,639 +52,413	+73%	+$1.91M	2.69%	10
2017 Q3	$2.62M	Buy	72,226 +39,012	+117%	+$1.12M	1.63%	21
2017 Q2	$922K	Buy	33,214 +15,000	+82%	+$396K	0.66%	43
2017 Q1	$510K	Sell	18,214 -34,786	-66%	-$879K	0.43%	54
2016 Q4	$1.07M	Buy	53,000 +22,250	+72%	+$444K	0.94%	36
2016 Q3	$618K	Sell	30,750 -22,491	-42%	-$371K	0.43%	53
2016 Q2	$707K	Hold	53,241	–	–	0.56%	50
2016 Q1	$988K	Hold	53,241	–	–	0.85%	37
2015 Q4	$975K	Hold	53,241	–	–	0.87%	34
2015 Q3	$942K	Sell	53,241 -40,300	-43%	-$785K	0.93%	32
2015 Q2	$1.65M	Hold	93,541	–	–	1.4%	26
2015 Q1	$1.62M	Buy	+93,541	New	+$1.7M	1.25%	23

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

DAFNA Capital Management's ASND Position: Q2 2026 in Review

DAFNA Capital Management increased its Ascendis Pharma A/S (ASND) stake by 109% in Q2 2026, buying an estimated $5.91M and bringing the position to 48,469 shares worth $12.9M. The position accounts for 2.47% of the portfolio, ranked #12.

DAFNA Capital Management first reported a position in ASND in Q1 2015 and has held it in 45 quarters since. The position peaked at $15.9M in Q4 2022. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

DAFNA Capital Management held 48,469 shares of Ascendis Pharma A/S worth $12.9M as of Q2 2026.
DAFNA Capital Management bought 25,292 Ascendis Pharma A/S shares in Q2 2026, an estimated $5.91M.
Ascendis Pharma A/S made up 2.47% of DAFNA Capital Management's portfolio in Q2 2026, its #12 holding.
DAFNA Capital Management first reported a position in Ascendis Pharma A/S in Q1 2015 and has held it in 45 quarters since.
DAFNA Capital Management's Ascendis Pharma A/S position peaked at $15.9M in Q4 2022.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.